Aurora Continues Deep Commitment to Veterans Through Strains for Heroes Initiative
EDMONTON, AB, July 16, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is proud to continue its Strains for Heroes initiative through collaboration with veteran communities and organizations across Canada. Five per cent of net profits from the sale of Strains for Heroes products are donated annually to veteran-focused organizations, up to a maximum of C$200,000.
"For the third consecutive year, we are honoured to stand alongside the veteran community, not just in compassion, but in action," says Geoff Hoover, SVP of Commercial Canada at Aurora. "Our commitment is embedded in how we listen, collaborate, and innovate with veterans to develop high-quality medical cannabis products that truly serve their needs. Their resilience inspires our mission, and their voices shape our products. Supporting those who've served our country is a responsibility we carry with pride."
Insights gained from veterans participating in the program help guide the company in crafting custom cannabis strains, focusing on attributes such as aroma, appearance, and effects that matter most to veteran patients. Since its launch in 2022, there have been five purpose-grown strains developed within the Strains for Heroes lineup, and named by veterans, including, Valour, Courage, Honour, Esprit De Corps and United Victory.
Aurora is proud to support a growing number of veteran-focused organizations, by participating in community outreach, making charitable donations and amplifying their voices. Some partners include, Highway for Heroes, Post Traumatic Growth Association, Quilts of Valour Canada, Rainbow Veterans of Canada, True Patriot Love, Veterans Association and 4Wheelers4Vets.
For more information about the Strains for Heroes product offerings and Aurora's veteran program, visit AuroraMedical.com.
About Aurora Cannabis Inc.
Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Information
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's Strains for Heroes initiative and support for veterans and veteran-focused organizations.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
14 minutes ago
- Cision Canada
Public health notice: Outbreak of Salmonella infections linked to various brands of salami and cacciatore products Français
: Update This outbreak investigation is ongoing. The public health notice will be updated as the investigation evolves. OTTAWA, ON, July 19, 2025 /CNW/ - At a glance Do not consume, use, sell, serve or distribute recalled salami and cacciatore products. For details on recalled product brand names and lot codes, please consult the Recalls and Safety Alerts website. Over 65 products have been recalled. These products may have been used in prepared products like sandwiches or sold at deli counters. Recalled food Recall warnings have been issued for various salami and cacciatore products, including products from brands: Bona Cosmo's Smoked Meats Imperial Meats Longos Luc's European Meats Cheese & Eats Marini Salumi Naturissimo P&E Foods Rea Speziale Fine Foods Superior Meats T.J. Meats Vince's Cured Meats Corp. These products were distributed to: Grocery stores Specialty markets Restaurants and cafés, delis, and butcher shops These products may have been used and sold in prepared products like sandwiches or at deli counters. These warnings were triggered by findings from the food safety investigation. For more information on the recalled products, including all product names, descriptions and lot codes, please consult the CFIA's notices on the Recalls and Safety Alerts website. How to protect your health Salmonellosis is a foodborne bacterial illness that can affect anyone exposed to a contaminated food product, including the recalled product. People who are infected with Salmonella bacteria can spread Salmonella to other people several days to several weeks after they have become infected, even if they don't have symptoms. The following advice applies to individuals, as well as retailers, distributors and food service establishments such as specialty markets, delis, and cafes across Canada: Check to see if you have the recalled products in your home or establishment by looking for the specific product name and size, UPC and codes in the recall alerts. Do not consume, serve, use, sell or distribute recalled products or any product made with them. Throw out or return recalled products to the location where they were purchased. Consumers or establishments who are unsure if they have purchased the recalled products are advised to contact their retailer or supplier where the products were purchased. Consumers who have purchased a prepared sandwich or meal and are unsure if it contains recalled products are advised to contact the retailer where the item was purchased. Do not cook food for other people if you've been diagnosed with a Salmonella infection or any other gastrointestinal illness. Contact your health care provider if you think you're experiencing symptoms of Salmonella. Most people who become ill from a Salmonella infection will recover fully after a few days without treatment, but it can also cause severe illness and hospitalization. The Salmonella strain associated with this outbreak investigation is multi drug-resistant, which means it's resistant to certain antibiotics (streptomycin, kanamycin, ampicillin, and sulfisoxazole). Other antibiotics are available to treat illnesses associated with this outbreak strain, if antibiotic treatment is considered necessary. Those at higher risk for serious illness include: Symptoms Salmonellosis has a wide range of symptoms. You may not get sick at all. However, if you do get sick, symptoms usually start within 6 to 72 hours after exposure. You may experience: chills a fever nausea diarrhea vomiting stomach cramps a sudden headache Most symptoms end within 4 to 7 days. While most people recover completely on their own, some people may have a more serious illness that: requires hospital care may lead to long-lasting health effects or death Salmonellosis (Salmonella) Food safety for vulnerable populations Investigation summary There are 87 laboratory-confirmed cases of Salmonella I 4,[5],12:i:- illness linked to this outbreak in: British Columbia (1) Alberta (68) Manitoba (1) Ontario (17) The illness reported in British Columbia is related to travel to Alberta. People became sick between mid-April and late-June 2025. Of the cases reported, nine people have been hospitalized and there have been no deaths. Many people who became sick reported eating salami in prepared sandwiches or purchased from deli counters where the recalled products were served. People who became sick are between 1 and over 100 years of age. More recent illnesses may continue to be reported in the outbreak because there is a period between when a person becomes ill and when the illness is reported to public health officials. For this outbreak, the illness reporting period is between 11 and 45 days. This outbreak may not be limited to the provinces with known illnesses. The recalled products were distributed to: Alberta British Columbia Saskatchewan Manitoba Ontario Quebec For more details on distribution please consult CFIA's notices on the . SOURCE Public Health Agency of Canada Contact us: Public Health Agency of Canada, Media Relations, Telephone: 613-957-2983, Email: [email protected]; Public inquiries, Telephone : 1-866-225-0709 (toll-free), Email: [email protected]
Globe and Mail
14 minutes ago
- Globe and Mail
Buy Microsoft Stock Now, or Wait for a Pullback?
Key Points Revenue growth accelerated in the company's most recently reported quarter. Microsoft is scheduled to report its fiscal fourth-quarter earnings later this month. The company pays a dividend, which should grow on an annual basis for the foreseeable future. 10 stocks we like better than Microsoft › Ahead of Microsoft 's (NASDAQ: MSFT) quarterly earnings release on July 30, many investors are likely looking closely at their shares of the software giant. After all, the stock has seen an incredible run recently. Shares are up 42% from April 21 to July 17. Not only has the stock benefited from a sharp V-shaped recovery following a tariff-related sell-off that impacted much of the market, but it has also risen to a new all-time high. The problem? The valuation is now questionably rich. To the company's credit, it's seeing impressive business momentum. Revenue and profit are both rising at double-digit rates, and the company appears well positioned to benefit from tailwinds in artificial intelligence (AI) -- both in terms of increased demand for its AI-related services and cost efficiencies as AI boosts employee productivity. But the big question is whether the stock has risen too far, too fast. Clearly, the company has great momentum. But has a sky-high valuation already priced in the bull case for this stock? Accelerating growth Microsoft's fiscal third-quarter results from late April (its most recently reported quarter) capture how well the company is doing -- and why investors are bidding shares higher. Revenue rose 13% year over year -- an acceleration from 12% growth in fiscal Q2. Notably, when adjusting for foreign exchange, fiscal third-quarter revenue actually rose 15% year over year. Additionally, operating income grew even faster, rising 16%, or 19% in constant currency. "Cloud and AI are the essential inputs for every business to expand output, reduce costs, and accelerate growth," said Microsoft CEO Satya Nadella in the company's fiscal third-quarter earnings release. "From AI infra and platforms to apps, we are innovating across the stack to deliver for our customers." Driving the quarter's results was a 21% year-over-year increase in revenue from the company's intelligent cloud segment. Included in this segment is the company's cloud-computing business, Azure. The cloud-powering infrastructure systems and software segment contributed 33% year-over-year revenue growth. But slower-growing segments still did well. For instance, Microsoft's revenue from its productivity and business processes segment rose 10% year over year, helped by growing Microsoft 365 subscriptions. High expectations Such broad-based strength, driven by lucrative software and services, makes a compelling case for the company's long-term growth potential. But with shares now trading at a price-to-earnings multiple of nearly 40, is the valuation simply too high? Given the stock's recent run-up, investors shouldn't get too excited. On the one hand, Microsoft's balanced business clearly deserves a high valuation multiple. After all, the company has a healthy balance sheet, a strong suite of products, and is seeing double-digit top- and bottom-line growth. However, a price-to-earnings ratio of 40 seems to price in plenty of optimism. Altogether, I'd lean more toward calling the stock a hold instead of a buy at the stock's current price. One reason I'm comfortable with this view, despite the stock's high valuation, is that the company takes some risk off the table every quarter by paying investors a quarterly dividend. Microsoft is a great dividend stock. Though its dividend yield is just 0.7%, there's plenty of room for this dividend payment to grow over time. This is evident by the fact that the company is paying out less than 25% of its earnings in dividends. Additionally, if history is any indication of the future, more dividend increases are likely. The company has increased its dividend every year for 23 years straight. Also helping the bull case is Microsoft's share repurchase program. With plenty of excess cash, the company is aggressively buying back its stock. Combining its dividends and repurchases, the company spent $9.7 billion returning capital to shareholders in fiscal Q3, up 15% year over year. Overall, Microsoft shares may not be a great buy at their current price. On the other hand, the company is giving shareholders plenty of reasons to hold onto their shares. But given the stock's premium valuation, shareholders should expect a bumpy ride. Should you invest $1,000 in Microsoft right now? Before you buy stock in Microsoft, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Microsoft wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
an hour ago
- Globe and Mail
Palantir Just Hit a Record High. What's the Smart Move Now?
Key Points The tech company's revenue growth rate accelerated in Q1. Palantir's commercial business in the U.S. is seeing explosive growth. The stock's wild valuation leaves no room for error. 10 stocks we like better than Palantir Technologies › Data and artificial intelligence company Palantir (NASDAQ: PLTR) seemed to defy gravity in 2024. Shares more than quadrupled, rising a staggering 340%. With such an incredible rise, you'd be forgiven for guessing that the stock would cool off in 2025. But, so far, the opposite is true. Shares are heating up, rising by more than 105% year to date as of this writing. This has given the tech stock a gain of approximately 800% since the start of 2024. With shares trading at record highs. What should investors do? Does it make sense to buy more shares and hope the momentum continues? Or should investors take a more cautious approach and hold or even sell the stock? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Soaring sales One thing Palantir really has going for it is its top-line growth. The tech company posted first-quarter revenue of $884 million, up 39% year over year. Highlighting the company's momentum, this was an acceleration from 36% year-over-year growth in the previous quarter. Fueling Palantir's first quarter of 2025 was 55% year-over-year growth in U.S. revenue. Accounting for $628 million of the quarter's total revenue, the U.S. market is vital for Palantir. Supporting this market was a 71% year-over-year increase in commercial revenue and a 45% jump in government revenue. Zooming out to all of the company's markets, Palantir said in its first-quarter update that it closed 139 deals worth $1 million or greater, 51 deals worth at least $5 million, and 31 deals worth $10 million or more. With these strong results now behind it, management had the confidence to raise full-year revenue guidance. The company said it now expects 2025 revenue to be between $3.890 billion and $3.902 billion. This compares to revenue of about $2.9 billion in 2024. The midpoint of management's 2025 revenue guidance range, therefore, assumes about 36% growth. This impressive top-line growth is bolstering profits. Palantir's first-quarter net income was approximately $214 million, more than double its profit of about $106 million in the year-ago quarter. Comments from Palantir co-founder and CEO Alexander Karp in the company's first-quarter earnings call suggest he believes the company is still in its early innings. "We are in the middle of a tectonic shift in the adoption of our software, particularly in the U.S..." Karp noted. "We are delivering the operating system for the modern enterprise in the era of AI." A valuation problem While Palantir's top-line momentum is certainly impressive, there's one big problem for investors: The market seems to have already priced in more rapid growth for years to come. Today, Palantir's market capitalization sits at about $365 billion -- more than 93 times the high end of management's guidance range for full-year 2025 revenue. Using the company's trailing-12-month sales, Palantir currently has a price-to-sales ratio of 123. This would be a high figure even for a price-to- earnings ratio. And what is Palantir's price-to-earnings ratio? It's 672. Yes, you heard that right. It's safe to say that investors have already bid up the stock to a level that prices in the most optimistic assumptions for this company. So, what should investors do? The decision is a personal one -- one that you'll have to make on your own. However, if I owned the stock, I'd sell. And for those who don't own shares, I'd avoid them like the plague at this price. Of course, I could be wrong. It's always possible that Palantir exceeds even my most bullish assumptions. Still, I believe there are likely better places with less risk and greater upside potential for investors to allocate their capital. Palantir is a great company. But expectations are simply too high. Investors would be wise to wait to see if they can buy shares at a better entry price. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
